US3290117A - Occult blood diagnostic composition with color enhancing agent - Google Patents

Occult blood diagnostic composition with color enhancing agent Download PDF

Info

Publication number
US3290117A
US3290117A US290253A US29025363A US3290117A US 3290117 A US3290117 A US 3290117A US 290253 A US290253 A US 290253A US 29025363 A US29025363 A US 29025363A US 3290117 A US3290117 A US 3290117A
Authority
US
United States
Prior art keywords
hydroperoxide
indicator
occult blood
color
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US290253A
Other languages
English (en)
Inventor
Jr Ernest Clarence Adams
Haitsma Cornelia Theodora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL126365D priority Critical patent/NL126365C/xx
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Priority to US290253A priority patent/US3290117A/en
Priority to DEM61333A priority patent/DE1242905B/de
Priority to CH817164A priority patent/CH446767A/de
Priority to BR160307/64A priority patent/BR6460307D0/pt
Priority to SE7629/64A priority patent/SE300717B/xx
Priority to FR979330A priority patent/FR1401656A/fr
Priority to BE649682A priority patent/BE649682A/xx
Priority to GB26150/64A priority patent/GB1057056A/en
Priority to NL6407185A priority patent/NL6407185A/xx
Priority to DK317064AA priority patent/DK115507B/da
Application granted granted Critical
Publication of US3290117A publication Critical patent/US3290117A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/725—Haemoglobin using peroxidative activity

Definitions

  • this invention is concerned with a diagnostic test which is useful for the qualitative detection and quantitative determination of blood in body fluids and products of elimination such as urine, vomitus, gastro-intestinal contents, cerebrospinal fluids and feces.
  • this invention is concerned with a highly sensitive reagent composition for the detection of occult blood which may be incorporated upon a bibulous carrier..
  • Blood is found in the gastric contents and in vomitus in conditions associated with erosion of gastric and intestinal mucuous membranes and, for example, ulcerous and carcinogenic conditions.
  • the regular and frequent occurrence of occult blood is suggestive of, for example, gastro-intestinal cancer, gastric or duodenal ulcers or hemorrhoids. Quite often, hemorrhage is so slight that it is no possible to detect the presence of blood by microscopic examination. Hence, a sensitive and specific diagnostic test for occult blood. is highly desirable.
  • the presence of blood cells or blood pigments may be indicative of a number of abnormal conditions, for example, typhus, scurvy, purpura, pyemia, nephritis, third degree burns, carcinogenic conditions of the urinary system, and as a result of the action of various hemolytic toxins and the like.
  • a simple and economical diagnostic test composition is provided which may advantageously be used with ease by hospital and clinical personnel untrained in laboratory technique as well .as the skilled laboratory technician and physician.
  • the inventive concept of the instant application is based on the catalytic activity of the prosthetic groups present in blood.
  • the catalytically active substances identified. in hemoglobin belong to the general class of hemoproteins, conjugate proteins, all of which have the same prosthetic groups, iron protoporphyrin or heme.
  • This prosthetic group has the ability to catalyze the oxidation of certain compounds by peroxides such as hydrogen peroxide, metal peroxides and organic peroxides. If the compound is an indicator or dye pre 3,290,117 Patented Dec. 6, 1966 cursor, colorless until it becomes oxidized and colored in its oxidized form, then the presence of the catalytic activity and hence the presence of blood is indicated by color formation.
  • the rapidity of the color change and the depth or density of the color when compared to a set of standards is a means of the quantitative estimation of the blood present.
  • quinoline derivatives found to be satisiactory as potentiating agents in the formulation of this where R may be hydrogen, methyl or hydroxy; R may be hydrogen, methyl or thiophenyl; R may be hydrogen or methyl or the substituted quinuclidine radical,
  • suitable potentiat-ing agents include quinoline; quinine; cinchonine; 6-methoxyquinoline; 4,6-dimethylquinoline; 6-methylquinoline; 7-methylquinoline; 2,6-dimethylquinoline; Z-methylquinoline (quinaldine); 8- amino-6-methoxyquinoline; 6-methoxy-3-phenylthioquino-' line; 8-methylquinoline; 2,3-dimethylquinoline 2-quinolinol; 2-methyl-8-quinolinol and 8-quino'1-r'nol.
  • each of the occult blood tests aforementioned may be improved by the addition of the quinoline or substituted quinoline potentiating agent.
  • the potentiating agent may be mixed with the dry compositions or tablets of U.S. Patent 2,290,436 to produce a diagnostic composition having greater sensitivity than the mixture of indicator peroxide and acidic material disclosed in the patent.
  • the tablets disclosed in U.S. Patent 2,799,660 comprising indicator peroxide buffer and effervescent couple and color contrast agent may be similarly improved by use of the potentiating agents of this invention.
  • the blood test of U.S. Patent 2,838,377 comprising an indicator, a peroxide and a bufier incorporated in a closed envelope formed of an electrolyte permeable sheet material may be similarly improved by the utilization of one or more of the various potentiating agents described above.
  • the occult blood tests described in U.S. Patent 3,012,- 976 comprise an organic hydroperoxide, an indicator and a buffer and may be improved by the inclusion therein of the potentiating agent of the instant invention.
  • the encapsulated compositions of U.S. Patent 3,092,463 may be likewise improved by use of a potentiating agent of the quinoline type.
  • the organic hydroperoxides of U.S. 3,092,464 are similarly improved.
  • a group of organic hydroperoxides having pronounced sensitivity in an indicator reaction may be encapsulated or entrapped with a colloidal material such as gelatin and the gelatin hardened by fixing with a dialdehyde polysaccharide.
  • a colloidal material such as gelatin
  • a dialdehyde polysaccharide a colloidal material
  • compositions of this invention may be prepared in solution or tablet form or may be used to impregnate a bibulous material such as paper, wood, fiber or the like, having any desired size or shape. Such products will undergo a distinct color change when contacted with an occult blood-containing specimen.
  • the group of organic hydroperoxides mentioned above which have been found to have the pronounced sensitivity which is required for the indicator reaction to be utilized in the diagnostic compositions of this invention comprise a group of materials including cu-mene hydroperoxide; diisopropylbenzene hydroperoxide; paramethane hydroperoxide; and 2,5-dimethy-lhexane, 2,5-dihydroperoxide; to mention a few of the significant members of this group.
  • Other organic hydroperoxides of similar structure may likewise be used if desired.
  • Organic hydroperoxides while producing outstanding results in various occult blood diagnostic compositions, have been found to be relatively unstable when mixed with the various other materials which are required in the provision of diagnostic compositions of this nature.
  • a novel encapsulating material is provide-d for the organic hydroperoxide.
  • This encapsulating material may be comprised of various protein or polysaccharide materials such as gelatin, algin, carrageenin, casein, albumin or other materials of this nature. These proteinaceous or 'polysaccharous materials are applied to the test compositions and then hardened by means of a fixing process which involves treating with a dialdehyde polysa-ccharide which is effective for this purpose.
  • buffering systems useful in the composition of this invention are tartrate, phosphate, phthalate, citrate and acetate buffer.
  • the preferred range of hydrogen ion concentration to which the composition is buifered is about pH 4 to pH 7.
  • dialdehyde polysaccharides sometimes known as periodate oxidized polysaccharides, for example, dialdehyde starch
  • Dialdehyde polysaccharides may be prepared by the well-known oxidation of polysaccharides with periodic acid. This preparation is illustrated by the conversion of starch to dialdehyde starch using periodic acid as the oxidizing agent in accordance with the below set-out equation wherein x stands for the number of repeating units in a molecule which may range from 20 to several thousand.
  • OHzOH CHzOH hyde polysaccharides which are from about 50% to oxidized, that is, in the case of dialdehyde starch, those wherein 50 to 100 per 100 of the original anhydroglucose units have been converted to dialdehyde units such as by periodate oxidation.
  • the dialdehyde polysaccharide is used in the form of an aqueous dispersion which may be readily prepared by adding the dialdehyde polysaccharide in the desired concentration, usually from about 0.25% to about 1.5%, to tap water or to a buffer solution and then mixing the aqueous dispersion with warming until a relatively homogenous dispersion is obtained.
  • the dialdehyde polysaccharide may be used in whatever concentration is required to satisfactorily harden the encapsulating material to provide the desired stability features. The precise concentration to be used will be pointed out more particularly hereafter.
  • emulsifying agent for example, acacia mucilage
  • Other emulsifying agents which may be used include polyvinyl alcohol, gum arabic, carboxy vinyl polymer, and the like.
  • a surfactant, or wetting agent may also be used.
  • sodium lauryl sulfate is used as a wetting agent, however, dioctyl sodium sulfosuccinate for example is also satisfactory.
  • An emulsifying agent when used serves to lower the surface tension of the oily organic hydroperoxide and forms a film around each individual oil droplet.
  • the surfactant assists in this regard and, in addition, produces an even diffusion of color on the diagnostic stick.
  • the resulting primary emulsion is buffered by means of an'appropriate buffer as discussed hereinabove.
  • the buffer in dilute form is first mixed with the material which is to form the capsule for the organic peroxide, for example, gelatin, before addition to the hydroperoxide emulsion. If the concentrated buffer is used with the encapsulating agent there is a tendency to precipitate the encapsulating agent prior to completion of the encapsulation. After the organic hydroperoxide has been entrapped or encapsulated, the concentrated buifer is added which has the effect of setting the encapsulation while controlling the pH and preventing false positives in testing.
  • aqueous dispersion of the dialdehyde polysaccharide is next added to serve as a fixing agent for the encapsulating material.
  • the encapsulation material which is present in the film around the oily organic hydroperoxide droplets is thereby fixed by the dialdehyde polysaccharide, resulting in a more stable preparation.
  • orthotolidine is the preferred indicator for the diagnostic compositions of this invention
  • various other indicator materials may be used so long as they satisfy the requirements pointed out above, namely, that they undergo a color change in the presence of an oxygen source and the blood for which the unknown material is being tested.
  • Such indicators comprise a variety of organic materials, principally those of aniline and phenol derivation.
  • quinoline itself or quinolines substituted in the 4-, 6- or 7-positions are used. Because of availability, economic reasons, and suitable physical properties, quinine has been found quite useful.
  • organic solvents found useful in the composition and methods of this invention are chloroform, ethylene dichloride, benzene and ethyl acetate.
  • the novel compositions of this invention may' be prepared in tablet form, a convenient tablet size being about /8" thick and about A" in diameter.
  • a drop of the material to be tested in the case of fecesan aqueous suspension of the specimen
  • a reagent tablet is placed in the center of the drop and activated by the adition of two drops of water to the tablet.
  • a positive test With a positive test, a ring of color appears on the filter paper surrounding the tablet, the color intensity varying, dependent upon the concentration of blood in the specimen. The color developed is then compared with a calibrated color chart to determine the concentration.
  • the dry composition may be added to a specific amount of water and mixed with the material to be tested. In the presence of occult blood, a color will be obtained. An estimation of the amount of occult blood present in the specimen may be made by comparing the color developed with calibrated standards.
  • compositions of the diagnostic material provided by this invention may vary within fairly wide limits in accordance with the general teachings set forth above.
  • Buffer II (489.0 g. sodium citrate plus 111.0 g. citric acid plus 1% liters water) was then added with mixing.
  • EXAMPLES 3 and 4 The testing reagents were prepared in accordance with Example 1, the quinine alkaloid ingredient being increased to 20 mg. and 50 mg. per 20 ml. respectively.
  • EXAMPLE 7 The hydroperoxide solution was prepared in accordance with that of Example 1.
  • the indicator solution was prepared to contain mg. o-tolidine, 10 mg. quinine alkaloid and 2 mg. polyoxyethylenenonylphenol per 20 ml. chloroform.
  • EXAMPLE 8 A hydroperoxide solution was prepared in accordance with that of Example 1.
  • the indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 6-methylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 ml.
  • EXAMPLE 9 A hydroperoxide solution was prepared in accordance wtih that of Example 1.
  • the indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 6-methylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 mg.
  • EXAMPLE 10 A hydroperoxide solution was prepared in accordance with that of Example 1.
  • the indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 7-methylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 ml.
  • EXAMPLE 1 1 A hydroperoxide solution was prepared in accordance with that of Example 1.
  • the indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 4,6-dimethylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 ml.
  • EXAMPLE 12 A hydroperoxide solution was prepared in accordance with that of Example 1.
  • the indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 2,6-dimethylquinoline and 2 mg. polyoxyethylenenonylphenol.
  • EXAMPLE 13 amount of o-tolidine in the formulation for the reason that o-tolidine is less soluble in benzene than in chloroform or ethylene dichloride. While it is not essential, it was unexpectedly discovered by observation under ultraviolet light that the addition of a surface-active agent, for example, polyoxyethylenenonylphenol, to the indicator solution resulted in a more even application of the color indicator and quinine alkaloid when prepared in a strip or stick form. It was found that the amount of surfaceactive agent could be varied over a range between 1 and 20 mg. per 20 ml., the preferred amount being in the lower end of the range.
  • a surface-active agent for example, polyoxyethylenenonylphenol
  • Bibulous sticks that is, absorbent paper out into narrow strips having dimensions of about 3" x /5" x 0.029, were dipped into the hydroperoxide solution followed by drying in a drying tunnel at a temperature of about 100 C.
  • the dried strips were subsequently heated in an oven at 70 C. for 8 to 16 hours to remove excess cumene hydroperoxide.
  • the strips were similarly dipped into the indicator solution and dried in a 70 C. oven or a 50 C. drying tunnel.
  • the finished impregnated strips were white to cream in color.
  • Table 1 sets out the results of 114 urine examinations from hospitalized patients, comparing the improved diagnostic test of this invention with prior known formulations.
  • TAB LE 1 Number Composition Applicants of Urines Cells per High Without Po Improved in Classi- Power Field tentiating Testing Comfication Agent position 62 Occasional 1 55 negatives 48 negatives 4 traces 5 traces 3 small 7 small 2 moderate 26 1-5 19 negatives 10 negatives 2 traces 1 trace 4 small 8 small 1 moderate 6 moderate 1 large 11 5-10 5 negatives 1 negative trace trace 2 small 3 small 4 moderate 4 moderate large 7 1020 3 negatives negative 1 trace 0 trace 2 small 3 small 1 moderate 4 moderate 8 20-50 2 negatives 0 negative 2 traces trace 2 small 3 small 2 moderate 3 moderate 2 large EXAMPLE 14 Benzidine method To 2 ml. of urine add 3 ml. saturated benzidine in glacial acetic acid (4 .g.O ml.) add 1 ml. of 3% hydrogen peroxide mix. A green to blue color indicates a positive reaction.
  • R is a member selected from the group consisting of hydrogen, methyl and methoxy
  • R is a member selected from the group consisting of hydrogen and methyl
  • R is a member selected from the group consisting of hydrogen, hy'droxy, methyl and amino.
  • composition of claim 1 wherein the potentiating agent is quinine.
  • composition of claim 1 wherein the potentiating agent is 6-methoxyquinoline.
  • composition of claim 1 wherein the potentiating agent is 6-methyl quinoline.
  • composition of claim 1 wherein the potentiating agent is 7-methyl quinoline.
  • composition of claim 1 wherein the potentiating agent is 4,6-dimethyl quinoline.
  • composition of claim 1 ing agent is quinoline.
  • composition of claim 1 wherein the organic hydroperoxide is a member selected from the group consisting of cumene hydroperoxide, diisopropylbenzene hydroperoxide, paramenthane hydroperoxide and 2,5-dimethylhexane-2,5-dihydroperoxide.
  • a composition for detecting blood which comprises an indicator capable of being oxidized in the presence of the prosthetic group of hemoglobin with an accompanying color change, an oxidizing agent effective to oxidize said indicator and a potentiating agent of the formula wherein the potentiatthiophenyl; R is a member selected from the group consisting of hydrogen, methyl and the radical E R is a member selected from the group consisting of hydrogen, methyl and methoxy; R is a member selected from the group consisting of hydrogen and methyl; and R is a member selected from the group consisting of hydrogen, hydroxy, methyl and amino.
  • composition according to claim 9 wherein the potentiating agent is a member selected from the group consisting of quinine, 6-methoxyquinoline, 6-methyl quinoline, 7-methyl quinoline, 4,6-dimethyl quinoline and quinoline.
  • a test indicator for detecting occult blood in body fluids and excreta comprising a bibulous material containing therein the dried residue resulting from the deposition on said material of a mixture comprising a first aqueous solution of an organic hydroperoxide, a buffer capable of maintaining the pH of the material being tested within the range of about 4 to 7, gelatin and as a fixative for said gelatin a dialdehyde polysaccharide, and a second solution of an indicator capable of being oxidized by the hydroperoxide in the presence of the prosthetic group of hemoglobin with an accompanying color change, a potentiating agent of the formula 19
  • R is a member selected from the group consisting of hydrogen, methyl and methoxy
  • R is a member selected from the group consisting of hydrogen and methyl
  • R is a member selected from the group consisting of hydrogen, hydroxy, methyl and amino and an organic solvent.
  • test indicator of claim 11 wherein the potentiating agent is 6-methoxyquinoline.
  • test indicator of claim 11 wherein the potentiating agent is 6-methyl quinoline.
  • test indicator of claim 11 wherein the potentiating agent is 7-methyl quinoline.
  • test indicator of claim 11 wherein the potentiating agent is 4,6-dimethyl quinoline.
  • test indicator of claim 11 wherein the potentiating agent is quinoline.
  • organic hydroperoxide is a member selected from the group consisting of cumene hydroperoxide, diisopropylbenzene hydroperoxide, paramethane hydroperoxide and 2,5-dirnethylheXane-2,5-dihydroperoxide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US290253A 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent Expired - Lifetime US3290117A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NL126365D NL126365C (enrdf_load_stackoverflow) 1963-06-24
US290253A US3290117A (en) 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent
DEM61333A DE1242905B (de) 1963-06-24 1964-06-11 Diagnostisches Mittel zum Nachweis und zur Bestimmung von Blut, insbesondere zur Bestimmung von okkultem Blut in Koerperfluessigkeiten und Ausscheidungsprodukten
BR160307/64A BR6460307D0 (pt) 1963-06-24 1964-06-23 Composicao e indicador de ensaio para descobrir sangue oculto em fluidos do corpo e excreta
SE7629/64A SE300717B (enrdf_load_stackoverflow) 1963-06-24 1964-06-23
FR979330A FR1401656A (fr) 1963-06-24 1964-06-23 Compositions sensibles pour la détermination colorimétrique de sang caché
CH817164A CH446767A (de) 1963-06-24 1964-06-23 Mittel zum Nachweis von Blut
BE649682A BE649682A (enrdf_load_stackoverflow) 1963-06-24 1964-06-24
GB26150/64A GB1057056A (en) 1963-06-24 1964-06-24 Occult blood compositions using quinoline compounds for increased sensitivity
NL6407185A NL6407185A (enrdf_load_stackoverflow) 1963-06-24 1964-06-24
DK317064AA DK115507B (da) 1963-06-24 1964-06-24 Middel til påvisning af blod i legemsvæsker og i ekskrementer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US290253A US3290117A (en) 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent

Publications (1)

Publication Number Publication Date
US3290117A true US3290117A (en) 1966-12-06

Family

ID=23115165

Family Applications (1)

Application Number Title Priority Date Filing Date
US290253A Expired - Lifetime US3290117A (en) 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent

Country Status (9)

Country Link
US (1) US3290117A (enrdf_load_stackoverflow)
BE (1) BE649682A (enrdf_load_stackoverflow)
BR (1) BR6460307D0 (enrdf_load_stackoverflow)
CH (1) CH446767A (enrdf_load_stackoverflow)
DE (1) DE1242905B (enrdf_load_stackoverflow)
DK (1) DK115507B (enrdf_load_stackoverflow)
GB (1) GB1057056A (enrdf_load_stackoverflow)
NL (2) NL6407185A (enrdf_load_stackoverflow)
SE (1) SE300717B (enrdf_load_stackoverflow)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630847A (en) * 1967-07-20 1971-12-28 Boehringer Mannheim Gmbh Diagnostic agent for use in the determination of hydroperoxides and of peroxidate-active substances
US3853472A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic test strip for the detection of components of body fluids
US3853471A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic composition for the detection of peroxidatively active substances in body fluids
US3975161A (en) * 1975-02-14 1976-08-17 Lachema, Narodni Podnik Biological diagnostic test strip
US3986833A (en) * 1975-09-08 1976-10-19 Miles Laboratories, Inc. Test composition, device, and method for the detection of peroxidatively active substances
US4017261A (en) * 1974-10-16 1977-04-12 Lachema, Narodni Podnik Biological diagnostic test strip and method of producing same
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4189304A (en) * 1978-10-27 1980-02-19 Miles Laboratories, Inc. Device and method for detecting myoglobin
EP0014929A1 (de) * 1979-02-14 1980-09-03 Roche Diagnostics GmbH Diagnostisches Mittel, Verfahren zu dessen Herstellung sowie dessen Verwendung zum Nachweis von Leukozyten in Körperflüssigkeiten
US4278439A (en) * 1979-12-17 1981-07-14 Miles Laboratories, Inc. Sensitizers for peroxidative activity tests
WO1982001070A1 (en) * 1980-09-24 1982-04-01 Minnesota Univ Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4539180A (en) * 1980-09-24 1985-09-03 Regents Of The University Of Minnesota Apparatus for quantitatively determining the level of hemoglobin in a biological sample
JPS61138163A (ja) * 1984-12-06 1986-06-25 イーストマン　コダツク　カンパニー 発色性カップラー及び過酸化水素又は他の被分析物の測定へのその使用
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
WO1989005972A1 (en) * 1987-12-24 1989-06-29 Litmus Concepts, Inc. Fecal occult blood test reagents and methods
US4845030A (en) * 1984-07-09 1989-07-04 Boehringer Mannheim Gmbh Use of aniline derivates as coupling components in oxidative color formation reactions
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US4971914A (en) * 1984-12-11 1990-11-20 Litmus Concepts, Inc. Developer for fecal occult blood tests
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5068197A (en) * 1984-12-11 1991-11-26 Litmus Concepts, Inc. Fecal occult blood test methods
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US5310680A (en) * 1987-09-16 1994-05-10 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5391498A (en) * 1987-09-16 1995-02-21 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5447868A (en) * 1993-09-14 1995-09-05 Propper Manufacturing Co. Inc. Method, reagent and kit for the detection of fecal occult blood
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US20020136436A1 (en) * 2001-02-23 2002-09-26 Schrier Wayne H. Devices and methods for reading and interpreting guaiac-based occult blood tests
US20110213229A1 (en) * 2008-11-13 2011-09-01 Mode Diagnostics Limited Electrode, electrochemical sensor and apparatus, and methods for operating the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1143634A (en) * 1980-06-02 1983-03-29 Alan E. Burkhardt Interference-resistant test device for determining a peroxidately active substance in a test sample and method for preparing it
DE3716891A1 (de) * 1987-05-20 1988-12-15 Boehringer Mannheim Gmbh Testkit zur bestimmung eines analyten im stuhl
AU8020398A (en) 1997-06-10 1998-12-30 Unilever Plc Method for enhancing the activity of an enzyme, bleach composition, detergent composition and process for inhibiting dye transfer
CN113176253B (zh) * 2021-04-21 2023-05-23 上海麦可信生物科技有限公司 动物排泄物隐血指示剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012976A (en) * 1959-11-02 1961-12-12 Miles Lab Specific test composition for occult blood
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012976A (en) * 1959-11-02 1961-12-12 Miles Lab Specific test composition for occult blood
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630847A (en) * 1967-07-20 1971-12-28 Boehringer Mannheim Gmbh Diagnostic agent for use in the determination of hydroperoxides and of peroxidate-active substances
US3853472A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic test strip for the detection of components of body fluids
US3853471A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic composition for the detection of peroxidatively active substances in body fluids
US4017261A (en) * 1974-10-16 1977-04-12 Lachema, Narodni Podnik Biological diagnostic test strip and method of producing same
US3975161A (en) * 1975-02-14 1976-08-17 Lachema, Narodni Podnik Biological diagnostic test strip
US3986833A (en) * 1975-09-08 1976-10-19 Miles Laboratories, Inc. Test composition, device, and method for the detection of peroxidatively active substances
JPS5233594A (en) * 1975-09-08 1977-03-14 Miles Lab Testing constitutes* instruments and methods for detection of peroxidation active substances
DE2640211A1 (de) * 1975-09-08 1977-04-07 Miles Lab Pruefmittel zum nachweis peroxidativ wirksamer substanzen
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4189304A (en) * 1978-10-27 1980-02-19 Miles Laboratories, Inc. Device and method for detecting myoglobin
EP0014929A1 (de) * 1979-02-14 1980-09-03 Roche Diagnostics GmbH Diagnostisches Mittel, Verfahren zu dessen Herstellung sowie dessen Verwendung zum Nachweis von Leukozyten in Körperflüssigkeiten
US4299917A (en) * 1979-02-14 1981-11-10 Boehringer Manneheim Gmbh Diagnostic agents for the detection of leukocytes in body fluids
US4278439A (en) * 1979-12-17 1981-07-14 Miles Laboratories, Inc. Sensitizers for peroxidative activity tests
WO1982001070A1 (en) * 1980-09-24 1982-04-01 Minnesota Univ Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4378971A (en) * 1980-09-24 1983-04-05 Regents Of The University Of Minnesota Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4539180A (en) * 1980-09-24 1985-09-03 Regents Of The University Of Minnesota Apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4845030A (en) * 1984-07-09 1989-07-04 Boehringer Mannheim Gmbh Use of aniline derivates as coupling components in oxidative color formation reactions
JPS61138163A (ja) * 1984-12-06 1986-06-25 イーストマン　コダツク　カンパニー 発色性カップラー及び過酸化水素又は他の被分析物の測定へのその使用
EP0184437A3 (en) * 1984-12-06 1988-03-16 Eastman Kodak Company Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes
US4971914A (en) * 1984-12-11 1990-11-20 Litmus Concepts, Inc. Developer for fecal occult blood tests
US5068197A (en) * 1984-12-11 1991-11-26 Litmus Concepts, Inc. Fecal occult blood test methods
US4939097A (en) * 1986-06-02 1990-07-03 Litmus Concepts, Inc. Fecal occult blood test methods
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5310680A (en) * 1987-09-16 1994-05-10 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5391498A (en) * 1987-09-16 1995-02-21 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
WO1989005972A1 (en) * 1987-12-24 1989-06-29 Litmus Concepts, Inc. Fecal occult blood test reagents and methods
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5447868A (en) * 1993-09-14 1995-09-05 Propper Manufacturing Co. Inc. Method, reagent and kit for the detection of fecal occult blood
US5563071A (en) * 1993-09-14 1996-10-08 Propper Manufacturing Co., Inc. Method, reagent and kit for the detection of fecal occult blood
US6410336B1 (en) 1993-09-14 2002-06-25 Propper Manufacturing Co., Ltd. Method reagent and kit for the detection of fecal occult blood
US20020136436A1 (en) * 2001-02-23 2002-09-26 Schrier Wayne H. Devices and methods for reading and interpreting guaiac-based occult blood tests
US6850633B2 (en) 2001-02-23 2005-02-01 Beckman Coulter, Inc. Devices and methods for reading and interpreting guaiac-based occult blood tests
US20110213229A1 (en) * 2008-11-13 2011-09-01 Mode Diagnostics Limited Electrode, electrochemical sensor and apparatus, and methods for operating the same
US9170265B2 (en) * 2008-11-13 2015-10-27 Mode Diagnostics Limited Electrode, electrochemical sensor and apparatus, and methods for operating the same

Also Published As

Publication number Publication date
SE300717B (enrdf_load_stackoverflow) 1968-05-06
DE1242905B (de) 1967-06-22
NL6407185A (enrdf_load_stackoverflow) 1964-12-28
NL126365C (enrdf_load_stackoverflow)
BE649682A (enrdf_load_stackoverflow) 1964-10-16
CH446767A (de) 1967-11-15
DK115507B (da) 1969-10-13
GB1057056A (en) 1967-02-01
BR6460307D0 (pt) 1973-09-11

Similar Documents

Publication Publication Date Title
US3290117A (en) Occult blood diagnostic composition with color enhancing agent
CA1052243A (en) Test composition, device, and method for the detection of peroxidatively active substances
US3853471A (en) Diagnostic composition for the detection of peroxidatively active substances in body fluids
US4148611A (en) Test composition, device and method for the detection of peroxidatively active substances
US3092463A (en) Stable blood detecting composition
DE69022393T2 (de) Verbesserte Zusammensetzung, Vorrichtung und Verfahren zur Untersuchung einer peroxidativ aktiven Substanz.
DE69013882T2 (de) Zusammensetzung, Vorrichtung und Verfahren zur Untersuchung einer peroxidativ aktiven Substanz.
US2290436A (en) Diagnostic composition and method
US4219336A (en) Diagnostic agent and method for the detection of occult blood in feces
JPS6322260B2 (enrdf_load_stackoverflow)
EP0121317B2 (en) Peroxidase activity detection composition
JPH04237500A (ja) ケトン体の検定のための組成物及び方法
US3001915A (en) Diagnostic composition
US3654180A (en) Indicator for detecting hydrogen peroxide and peroxidative compounds containing alpha naphthoflavone
JPH066073B2 (ja) ヘモグロビンのペルオキシダ−ゼ様活性測定のための組成物および方法
JPS5887461A (ja) 分析素子の製造方法
TW438976B (en) Improved method for the detection of protein
US3016292A (en) Diagnostic composition
US4132527A (en) Diagnostic compositions, diagnosing instruments, and methods of manufacturing same
CA1041408A (en) Diagnostic agent for sacaharides
EP2040074B1 (en) Method for assaying urine albumin
US4676950A (en) Indicator and test device for detecting occult blood
JP2860660B2 (ja) 新規な潜血検出用試験片。
JPS6010261B2 (ja) 潜血検出用組成物
US3645688A (en) Measuring triglyceride and cholesterol in blood plasma or serum